Advancing drug innovation for neglected diseases-criteria for lead progression.
The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Ac...
Збережено в:
Автори: | , , , , , |
---|---|
Формат: | Книга |
Опубліковано: |
Public Library of Science (PLoS),
2009-08-01T00:00:00Z.
|
Предмети: | |
Онлайн доступ: | Connect to this object online. |
Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Інтернет
Connect to this object online.3rd Floor Main Library
Шифр: |
A1234.567 |
---|---|
Примірник 1 | Доступно |